2020-05-31: Un-audited Financial Statement (correction)

ORIONPHARM: (Quarter 3) (correction) As per un-audited financial statements of Orion Pharma Ltd., Consolidated EPS was Tk. 0.61 for January-March 2020 as against Tk. 0.95 for January-March 2019; Consolidated EPS was Tk. 2.75 for July'19-March'20 as against Tk. 3.01 for July'18-March'19. Consolidated NOCFPS was Tk. 2.73 for July'19-March'20 as against Tk. 7.15 for July'18-March'19. Consolidated NAV per share (excluding Revaluation Surplus) was Tk. 68.57 as on March 31, 2020 and Tk. 66.05 as on March 31, 2019. NAV per share (including Revaluation Surplus) was Tk. 76.68 as on March 31, 2020 and Tk. 74.29 as on March 31, 2019.